HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report
2011

Using HE4 and CA125 for Diagnosing Pelvic Masses

Sample size: 1 publication Evidence: moderate

Author Information

Author(s): Anastasi Emanuela, Granato Teresa, Coppa Anna, Manganaro Lucia, Giannini Giuseppe, Comploj Sara, Frati Luigi, Midulla Cecilia

Primary Institution: Sapienza University, Rome

Hypothesis

Can HE4 and CA125 serum concentrations improve the differential diagnosis of pelvic masses in high-risk patients?

Conclusion

The combination of HE4 and CA125 serum concentrations can enhance the accuracy of diagnosing pelvic masses in patients at high risk for ovarian cancer.

Supporting Evidence

  • HE4 is expressed in early stages of ovarian cancer and can indicate disease recurrence.
  • The patient had a 50% chance of being a BRCA1 mutation carrier due to family history.
  • Low levels of HE4 suggested a non-malignant lesion in the patient.
  • Combining HE4 and CA125 with imaging techniques improves diagnostic accuracy.

Takeaway

Doctors can use blood tests for HE4 and CA125 to help figure out if a pelvic mass is dangerous or not, especially in women with a family history of cancer.

Methodology

The study involved serum analysis of HE4 and CA125 biomarkers, pelvic ultrasound, and MRI imaging.

Limitations

The patient refused genetic testing and oncogenetic counseling, which limited the ability to assess her individual risk accurately.

Participant Demographics

A 24-year-old woman with a strong family history of breast cancer.

Digital Object Identifier (DOI)

10.3390/ijms12010627

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication